Quantcast
Last updated on April 19, 2014 at 13:20 EDT

Latest flutamide Stories

2010-11-10 18:25:11

Men taking androgen deprivation therapy (ADT) for prostate cancer may have an increased risk of colorectal cancer, according to a study published online November 10 in The Journal of the National Cancer Institute. Androgen deprivation therapy is a widely-prescribed treatment in men with prostate cancer, although its usage for low-risk disease remains controversial, given the adverse side effects, including osteoporosis, cardiovascular disease, diabetes and obesity; the last two are risk...

2010-07-07 13:31:11

In its early stages, prostate cancer requires androgens (hormones that promote the development and maintenance of male sex characteristics) for growth, and current first-line therapies target the receptor for these hormones to slow cancer's development and spread. However, advanced prostate cancers are often androgen-independent, meaning that androgen-blocking therapies are ineffective. Scientists aren't sure how this shift occurs as prostate cancer advances. One idea is that prostate cancer...

2009-04-10 15:36:38

A new therapy for metastatic prostate cancer has shown considerable promise in early clinical trials involving patients whose disease has become resistant to current drugs. Chemists and biologists at UCLA and colleagues at several other institutions, including Memorial Sloan-Kettering Cancer Center, have created a new drug to treat a particularly lethal form of the disease, known as castration-resistant prostate cancer, or CRPC. Also referred to as hormone-refractory prostate cancer, CRPC is...

2009-04-08 13:51:06

U.S. medical scientists say two new drugs designed to treat metastatic prostate cancer have shown considerable promise in early clinical trials. The Howard Hughes Medical Institute researchers said of 30 men who received low doses of one the drugs in a multi-site phase I/II trial designed to evaluate safety, 22 showed a sustained decline in the level of prostate specific antigen in their blood. Phase III clinical trials are planned to evaluate the drug's effect on survival in a large group of...

2008-12-31 16:15:39

Hormone deprivation therapy that prostate cancer patients often take gives them only a temporary fix, but U.S. researchers suggest why. Jun Luo of Johns Hopkins University and colleagues at the University of Washington and Puget Sound VA Medical Center said they have discovered critical differences in the hormone receptors on prostate cancer cells in patients who no longer respond to this therapy. Prostate cancer cells rely on androgens -- male hormones that include testosterone -- to...

2008-12-03 13:24:14

Degarelix avoids initial hormone surge seen in other drugsMore than 95 per cent of men who took degarelix for prostate cancer saw their testosterone levels fall dramatically as early as three days after they started treatment, according to a paper in the December issue of BJU International.They also experienced much greater falls in their prostate-specific antigen (PSA) levels at 14 and 28 days than men taking leuprolide.Researchers from Canada, the USA, France, Denmark and the Netherlands...

2008-09-22 15:00:14

WILMINGTON, Del., Sept. 22 /PRNewswire-FirstCall/ -- AstraZeneca today announced that the United States Food and Drug Administration (FDA) has granted an additional six-month period of exclusivity to market CASODEX(R) (bicalutamide) for its licensed advanced prostate cancer indication until April 1, 2009. AstraZeneca has been working with the FDA in the investigation of the safety and effectiveness of CASODEX in a pediatric setting but will not be seeking an indication in this population....

2008-08-22 15:00:17

Some drugs given to men to help treat prostate cancer may actually spur some cancer cells to grow, U.S. researchers said. The study, published online in two papers in the Proceedings of the National Academy of Sciences, said hormone therapy, a common treatment for men with advanced prostate cancer, generally keeps the cancer at bay for a year or two. But then, for reasons scientists have never understood, the treatment fails in patients whose disease has spread. Chawnshang Chang,...

2008-07-28 18:00:17

SCIENTISTS are hailing a new drug to treat aggressive prostate cancer as potentially the most significant advance in the field for 70 years. Abiraterone could treat up to 80% of patients with a deadly form of the disease resistant to currently available chemotherapy, they said. The drug works by blocking the hormones which fuel the cancer. The Institute of Cancer Research hopes a simple pill form will be available in two to three years. An advanced clinical trial involving 1,200...

2008-07-22 09:01:13

Ambrilia Biopharma has initiated a Phase I/II clinical development program of its proprietary, novel three-month formulation of goserelin, in hormone-sensitive prostate cancer patients. The study is designed to assess the hormonal efficacy, pharmacokinetic and safety of its formulation of goserelin (Zoladex) in prostate cancer patients. The goserelin formulation is manufactured by Ambrilia at its good manufacturing practice facilities in Montreal, and the company aims to divest this...